Talk:Strontium ranelate

A company in the United States called Osteologix is pursuing a drug called strontium malonate. From the decision in the European Patent Office it appears to have better bioavailability than strontium ranelate. Strontium Malonate is also a pill as opposed to a sachet.

Osteologix Prevails in European Patent Opposition for Osteoporosis Drug EPO Division Finds Use of NB S101 Novel with Superior Bioavailability Over Protelos®

Tuesday March 31, 2009, 8:01 am EDT

GLEN ALLEN, Va.--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB:OLGX - News) today announced that the European Patent Office (EPO) has upheld the validity of the company's European Patent No. EP 1,534,305 B9, "Treating Cartilage and Bone Conditions with Water Soluble Strontium Salts". This patent offers protection for the use of NB S101(strontium malonate) for the treatment of osteoporosis and related conditions while confirming that the innovative product, NB S101, demonstrated a significant increase in bioavailability over the EMEA approved Protelos® (strontium ranelate).

The EPO originally issued the patent in October 2006, with an expiration date in May 2024. In July 2007, Intellectual Property Services (I.P.S.) of Paris, France, filed Notice of Opposition against the Osteologix European Patent, requesting revocation of the patent in its entirety. In March 2009, the Opposition Division upheld the Osteologix patent without changes and rejected I.P.S.'s request to revoke the Osteologix patent.